- Details
- Scott Tagawa joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses advances in bladder and prostate cancer. He highlights his recent work on antibody-drug conjugates (ADCs) specifically, sacituzumab govitecan in metastatic urothelial cancer and the and the initial results from TROPHY-U-01. Although immune checkpoint inhibitors now provide an...
|
- Details
- In this conversation, Alicia Morgans and Cora Sternberg, Medical Oncologist and Clinical Director of the Englander Institute for Precision Medicine, Weill Cornell Medicine in New York discuss the recently presented results from the CARD trial. The CARD Trial a phase 4 clinical trial compared cabazitaxel vs abiraterone or enzalutamide in patients who were previously treated with docetaxel and had p...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Charles Ryan is joined by his colleague Aaron Le Beau from the University of Minnesota who specializes in the developments of targeted imaging agents and therapeutics for prostate cancer using novel antibody constructs. Drs. Ryan and LeBeau discuss the work he is doing on potential alternate targets to PSMA. Antibodies we...
|
- Details
- Alexander Wyatt from the University of British Columbia joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to talk about the current state of cell-free DNA and what a clinician can use in the treatment of prostate cancer from cell-free DNA for current testing. Biographies: Alexander Wyatt, Ph.D., BSc, Assistant Professor, Department of Urologic Sciences,...
|
- Details
- Akash Patnaik, an Assistant Professor of Medicine at the University of Chicago joins Alicia Morgans to speak about his work and expertise with immunotherapy in prostate cancer. Dr. Patnaik and Dr. Morgans discuss the work that he is doing in the lab to better understand why some patients have exceptional responses to combining two different immunotherapies targeting CTLA-4 and PD-1 in prostate can...
|
- Details
- Bertrand Tombal presents the recently published results from the CARD trial: "CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent". Enzalutamide in Metastatic Prostate Cancer (mCRPC) is highly heterogeneous with the coe...
|
- Details
- Charles Drake, a leader in the research of immunology in castration-resistant prostate cancer, (mCRPC) discusses the evolution of immunotherapy in prostate cancer. Together with Charles Ryan, in this discussion, he focuses on the best combination therapies and MSI-high disease in metastatic prostate cancer. Biographies: Charles G. Drake, MD, Ph.D., Department of Medicine, Division of Hematology/On...
|
- Details
- Arpit Rao joins Alicia Morgans to discuss new data on PARP inhibitors in prostate cancer. Dr. Rao shares his thoughts about the future of PARP, where things stand with PARP inhibitors currently, highlighting the PROfound study, TRITON2, and last year's TOPARP-B in advanced castration-resistant prostate cancer and what he thinks in terms of personalized medicine for this population. Biographies: Ar...
|
- Details
- Cora Sternberg joins Alicia Morgans and shares highlights from the Management of castration-resistant prostate cancer session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) and key takeaways from the session when thinking about managing these patients with this disease. She highlights Professor Michael Hofman's presentation on PSMA Targeted Therapies focusing on Lutetium PSMA sc...
|
- Details
- Mary-Ellen Taplin joins Alicia Morgans to share highlights from her 2019 Advanced Prostate Cancer Consensus Conference (APCCC) presentation on first line treatment of metastatic castration-resistant prostate cancer (mCRPC) after patients have received either docetaxel or abiraterone, enzalutamide, or apalutamide and the lack of data to guide treating physicians in this treatment setting. She highl...
|
